Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Noticed the below on Amigo loans website. It probably is nothing but you never know
Please note: Our phone lines will be closed from 3:45pm today, 11th November. We'll be open again from 9am tomorrow. We apologise for any inconvenience. If you need help with payments, checking your balance or updating your details, please head to your online account: amigoloans.co.uk/login.
Tullow’s CEO, Rahul Dhir, is in Kenya this week with our JV partners to discuss the revised development plan for Project Oil Kenya with key stakeholders.
https://twitter.com/TullowOilplc/status/1453635813091258370
No problem Mousekewitz. Just received below email from them.
Thanks for your query regarding the Risers/Fallers function of the website.
The Risers/Fallers list is index specific so to qualify any share would need to be on the relevant index. In the case of Amigo Holdings it is not listed on the FTSE all share so would not qualify to be on the list.
The FTSE UK Index Series is reviewed on a quarterly basis so shares can be listed in the future if they qualify.
I hope this has been of assistance.
Amigo again fails to show on HL top share risers table . Had spoken with HL and they said will investigate and get back to me. They did say it currently is marked not applicable under company indices, and that the London Stock Exchange reviews independently on a quarterly basis.
Good spot Yuri. Link group are identified on the Amigo contacts as registrars contact. This was only added this year under Amigo web contacts. I have tried to contact Link Group but kept on hold. Would be good to verify reasoning behind change.
RBC Capital Markets upgraded its stance on shares of fast-fashion retailer Boohoo on Tuesday to ‘outperform’ from ‘sector perform’ and lifted the price target to 410p from 380p..
https://www.sharecast.com/news/broker-recommendations/boohoo-attractively-valued-says-rbc-capital--8034695.html
Amigo has appointed a new Chief Customer Officer (https://www.amigoplc.com/directors-and-company-secretary).
Jake joined Amigo in June 2021. As Chief Customer Officer he leads the marketing and distribution strategies that deliver Amigo’s brand goal of widening mainstream financial inclusion and bringing about positive customer outcomes. Jake spent over a decade at Equifax where, as European Chief Marketing Officer, he led strategy, product, pricing, and marketing and played a key role in delivering its transformation and reputation rebuild programmes. Jake also brings industry experience from ClearScore and most recently Freedom Finance where his product team won numerous awards for their work on widening access to affordable credit using Open Banking technology. Jake has a BA in history and postgraduate qualifications from the LSE and Ashridge.
I just checked on Linkedin and shows the below statement from the new HR Director.
Today joined the leadership team at Amigo Loans.
First impressions are great.
Yes, it is a business in the eye of a storm but I look forward to dancing in the rain and brighter days ahead.
Life would be boring if it was all rainbows and butterfly's right?
Not sure if it helps but the below is the last response I received from 4D IR, when asking what are the benefits in moving across to LBRS listing.
While one might expect prices on the two exchanges to roughly align this is in no way guaranteed, and is based on an assumption of completely free movement between the two exchanges. In practice such transfers are subject to various sources of friction such as exchange rates, time zones / market opening times, and are not instantaneous.
Over time we might expect greater volumes to be traded in the US, increasing the liquidity of Nasdaq holdings. Further, the generally more specialist healthcare investors of the US markets might be expected to respond differently, or to a greater or lesser degree, to 4D pharma announcements as well as external factors - from announcements by other companies with potential ‘read through’ to 4D programs or broader market conditions. Holding Nasdaq ADSs would allow holders to be involved in and potentially benefit from this. Again, there is no certainty that AIM-listed ordinary shares will necessarily track Nasdaq ADSs.
Sorry for the delayed response. As per DDDD IR response below, they would expect the share value will be closely aligned on both AIM and ADS . I had asked DDDD IR if this is the case ,what are the benefits in converting the AIM to ADS shares. I will forward the response to you once received.
"AIM: DDDD and NASDAQ: LBPS both trade on their respective exchanges independently, however we would expect the prices to roughly track one another, with 1 ‘LBPS’ ADS representing 8 AIM ‘DDDD’ ordinary shares (and factoring in things like £:$ exchange rate). The reason for this is that if the two listings were to hypothetically have a significant price disparity, holders would be incentivised to convert their holding on the cheaper exchange to sell on the more expensive exchange, to exploit the arbitrage opportunity. This change in respective supply and demand would effect the price of each, and thus we would expect the two to reach a rough equilibrium and track over time."
I had asked 4D of benefits in transferring from ordinary shares to ADS and received the below response. Hope it helps.
Thanks for getting in touch. As stated in today’s guidance – no, holders of AIM ordinary shares who do not wish to convert to Nasdaq ADSs but wish to remain a holder of 4D pharma do not need to take any action, 4D pharma’s ordinary shares listed on AIM will continue to trade as they currently do.
To your second point, while we are unable to comment definitively on the potential benefits of holding ADSs, we might expect doing so to allow holders to benefit from the increased exposure of 4D pharma to the US capital markets and particularly the specialist healthcare investment environment, which should allow 4D pharma to realise the full value of its pipeline of LBPs, MicroRx® platform, intellectual property and drug discovery and development activities. Over time we might also expect to see greater trading volumes and liquidity in the US market vs the UK.
Nasdaq is the world’s premier market for public biotechnology companies. There are over seven times as many listed healthcare companies in the US as there are in the UK, that amount to a market value worth roughly 17 times that of UK-listed healthcare companies. Converting 4D pharma ordinary shares to Nasdaq-listed ADSs provide holders an opportunity to be part of this action.
I hope that answers your query, thank you for you continued interest and support of 4D pharma.